Impact Partnership Wealth’s ADMA Biologics ADMA Stock Holding History

Impact Partnership Wealth’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-424	Closed	-$1.56K	–	993
2023 Q2	$1.56K	Buy	+424	New	+$1.57K	﹤0.01%	727

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Impact Partnership Wealth's ADMA Position: Q3 2023 in Review

Impact Partnership Wealth sold out of ADMA Biologics (ADMA) in Q3 2023, closing a stake of 424 shares — an estimated $1.56K sold.

Impact Partnership Wealth first reported a position in ADMA in Q2 2023 and held it in 1 quarter. The position peaked at $1.56K in Q2 2023. 188 funds tracked by Wall St. Rank hold ADMA as of Q3 2023.

Impact Partnership Wealth reported no remaining ADMA Biologics position as of Q3 2023 after selling out during the quarter.
Impact Partnership Wealth sold 424 ADMA Biologics shares in Q3 2023, an estimated $1.56K.
Impact Partnership Wealth first reported a position in ADMA Biologics in Q2 2023 and held it in 1 quarter.
Impact Partnership Wealth's ADMA Biologics position peaked at $1.56K in Q2 2023.
188 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2023.

Based on Impact Partnership Wealth's 13F filing for Q3 2023, filed 17 Oct 2023.